Celltrion Co. announced that its Remsima SC autoimmune drug reached a 22% market share in Europe by end-2024, marking a fivefold increase in four years, with the full Remsima portfolio capturing 71% of the market.
#YonhapInfomax #Celltrion #RemsimaSC #MarketShare #Europe #BiosimilarGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65060

Celltrion sees potential for expanded biosimilar prescriptions following US drug price reduction measures, expecting limited impact on its products and positive opportunities for sales activities.
#YonhapInfomax #Celltrion #Biosimilars #DrugPriceReduction #USHealthcare #PrescriptionDrugs #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64175

Celltrion announces 100 billion won share buyback, signaling confidence in company value amid market uncertainties and commitment to shareholder returns
#YonhapInfomax #Celltrion #ShareBuyback #TreasuryShares #CorporateValue #ShareholderValue #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=63924

Celltrion Chairman Seo Jung-jin sees US drug price cuts as an opportunity, maintains 5 trillion won sales target, and plans to decide on US factory by year-end.
#YonhapInfomax #Celltrion #DrugPriceCuts #Biosimilars #USTariffs #CDMOFactory #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=63348

Celltrion sees growth opportunities in US drug price reduction executive order, anticipating market expansion through improved distribution structure and direct price negotiations with government.
#YonhapInfomax #Celltrion #DrugPriceReduction #ExecutiveOrder #Biosimilars #MarketExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=63004

Celltrion announces 100 billion won share cancellation, continuing aggressive shareholder return policy amid market uncertainties and undervaluation concerns
#YonhapInfomax #Celltrion #ShareCancellation #TreasuryShares #ShareholderValue #CorporateGovernance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62729

Celltrion reports Q1 operating profit surge of 868% to 149.4 billion won, driven by strong sales of follow-up products and improved cost efficiency post-merger
#YonhapInfomax #Celltrion #Q1Earnings #OperatingProfit #Biosimilars #PharmaceuticalIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62540

Celltrion reports Q1 operating profit of 149.4 billion won, up 868% year-on-year, but falls short of market expectations despite significant growth
#YonhapInfomax #Celltrion #Q1Earnings #OperatingProfit #MarketExpectations #BiopharmaceuticalIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62527

Celltrion reports significant Q1 profit growth, but falls short of market expectations, signaling potential challenges in the biopharmaceutical sector
#YonhapInfomax #Celltrion #Q1Earnings #OperatingProfit #BiopharmaceuticalIndustry #MarketExpectations #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62519

Celltrion explores US-based API production facilities to mitigate potential Trump administration drug tariffs, implements short-term inventory transfer and medium-term local production strategies.
#YonhapInfomax #Celltrion #DrugTariffs #APIProduction #USManufacturing #PharmaceuticalIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61960

Celltrion's Q1 results expected to miss market estimates due to decreased sales of existing products and increased costs for US tariff preparation, despite significant year-on-year profit growth attributed to base effects.
#YonhapInfomax #Celltrion #Q1Performance #USTariffs #BiosimilarSales #OperatingProfit #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61864

Celltrion announces 100 billion won share buyback, part of larger 650 billion won group-wide purchase plan, amid perceived undervaluation and commitment to shareholder value
#YonhapInfomax #Celltrion #ShareBuyback #TreasuryShares #ShareholderValue #CorporateGovernance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=60666

Celltrion maintains strong financial position despite increased borrowing, with focus on future investments and shareholder returns amid merger effects and improving market conditions.
#YonhapInfomax #Celltrion #FinancialStability #Borrowing #InvestmentPlans #MergerEffects #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=59889

Celltrion's cancer drug Herzuma secures extended supply in Brazil until 2026, strengthening its position in Latin American markets
#YonhapInfomax #Celltrion #Herzuma #BrazilSupply #CancerTreatment #LatinAmericanMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=59080

Celltrion's Yuflyma gains FDA approval for interchangeability with Humira, boosting its competitive edge in the lucrative U.S. autoimmune disease treatment market
#YonhapInfomax #Celltrion #Yuflyma #Humira #Interchangeability #FDAApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=58524

Celltrion Chairman Seo Jung-jin to purchase 50 billion won worth of company shares, with affiliates acquiring additional 150 billion won, signaling confidence in future growth amid undervaluation concerns.
#YonhapInfomax #Celltrion #SeoJungJin #SharePurchase #ShareholderValue #CDMOCollaboration #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=57928

Celltrion announces third share buyback of the year, totaling 100 billion won, to enhance shareholder value amid market uncertainties
#YonhapInfomax #Celltrion #ShareBuyback #ShareholderValue #TreasuryShares #CorporateStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=56895

Celltrion announces plans to protect shareholder interests through share buybacks and cancellations amid global economic uncertainties, particularly focusing on upcoming US tariff policy.
#YonhapInfomax #Celltrion #ShareholderValue #USTariffPolicy #ShareBuyback #CorporateGovernance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=56766

Celltrion announces decision to cancel all 50 billion won worth of treasury shares, continuing aggressive shareholder return policy amid global pharma ambitions
#YonhapInfomax #Celltrion #TreasuryShares #ShareCancellation #ShareholderReturn #GlobalBigPharma #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=56694

Celltrion re-elects founder Seo Jung-jin as internal director, highlighting his role in driving innovation and growth in the pharmaceutical industry
#YonhapInfomax #Celltrion #SeoJungJin #InternalDirector #PharmaceuticalIndustry #Biosimilars #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=55540